Watanabe S, Saito S, Yoshikawa A, Shibayama T, Kamimura T, Suzuki S, Ischida F
Hepatogastroenterology. 1982 Jun;29(3):102-5.
Five male patients with HbsAg-positive liver disease were treated with ara-A at dosages ranging between 5 mg and 10 mg/kg/day for five days. Before treatment, all of them had detectable DNA polymerase activity and HbeAg in their sera. The five-day course of the drug resulted in a rapid fall in DNA polymerase activity in every patient, the effect being dose-dependent. The amount of circulating Dane particles also decreased simultaneously, or with a short time lag, with the fall of the enzyme activity. The following decrease in HBeAg concentration was observed in all patients, and it was also noteworthy that antiHBe response was found in two of the five. HBsAg titers were significantly diminished in two patients. In the present series of ara-A treatment, these effects were temporary in two patients, while, in the remaining three, they lasted for two to three months. Ara-A had no serious side effects at dosages of 10 mg/kg/day or less, and can thus be counted among the valuable therapeutic drugs against chronic HBV infection.
五名乙肝表面抗原（HbsAg）阳性肝病男性患者接受了阿糖腺苷（ara - A）治疗，剂量为5毫克至10毫克/千克/天，持续五天。治疗前，他们所有人血清中均可检测到DNA聚合酶活性和e抗原（HbeAg）。为期五天的药物疗程使每位患者的DNA聚合酶活性迅速下降，且该效果呈剂量依赖性。循环中的丹氏颗粒数量也随着酶活性的下降而同时或短时间滞后减少。所有患者均观察到随后e抗原浓度降低，同样值得注意的是，五名患者中有两名出现了抗e抗体（antiHBe）反应。两名患者的乙肝表面抗原（HBsAg）滴度显著降低。在本系列阿糖腺苷治疗中，这些效果在两名患者中是暂时的，而在其余三名患者中持续了两到三个月。阿糖腺苷在剂量为10毫克/千克/天或更低时没有严重副作用，因此可被视为对抗慢性乙肝病毒（HBV）感染的有价值治疗药物。
